Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 533

1.

Lipid Nanoparticles for Cell-Specific in Vivo Targeted Delivery of Nucleic Acids.

Khalil IA, Younis MA, Kimura S, Harashima H.

Biol Pharm Bull. 2020;43(4):584-595. doi: 10.1248/bpb.b19-00743.

2.

Different kinetics for the hepatic uptake of lipid nanoparticles between the apolipoprotein E/low density lipoprotein receptor and the N-acetyl-d-galactosamine/asialoglycoprotein receptor pathway.

Sato Y, Kinami Y, Hashiba K, Harashima H.

J Control Release. 2020 Mar 5;322:217-226. doi: 10.1016/j.jconrel.2020.03.006. [Epub ahead of print]

PMID:
32145269
3.

Vitamin E Scaffolds of pH-Responsive Lipid Nanoparticles as DNA Vaccines in Cancer and Protozoan Infection.

Maeta M, Miura N, Tanaka H, Nakamura T, Kawanishi R, Nishikawa Y, Asano K, Tanaka M, Tamagawa S, Nakai Y, Tange K, Yoshioka H, Harashima H, Akita H.

Mol Pharm. 2020 Apr 6;17(4):1237-1247. doi: 10.1021/acs.molpharmaceut.9b01262. Epub 2020 Mar 4.

PMID:
32129629
4.

Development of a nanoparticle that releases nucleic acids in response to a mitochondrial environment.

Yamada Y, Fukuda Y, Sasaki D, Maruyama M, Harashima H.

Mitochondrion. 2020 Feb 22;52:67-74. doi: 10.1016/j.mito.2020.02.009. [Epub ahead of print]

PMID:
32097722
5.

Improved Stability of siRNA-Loaded Lipid Nanoparticles Prepared with a PEG-Monoacyl Fatty Acid Facilitates Ligand-Mediated siRNA Delivery.

Sakurai Y, Mizumura W, Ito K, Iwasaki K, Katoh T, Goto Y, Suga H, Harashima H.

Mol Pharm. 2020 Apr 6;17(4):1397-1404. doi: 10.1021/acs.molpharmaceut.0c00087. Epub 2020 Mar 2.

PMID:
32091909
6.

Involvement of Caveolin-1-mediated transcytosis in the intratumoral accumulation of liposomes.

Sakurai Y, Kato A, Harashima H.

Biochem Biophys Res Commun. 2020 Apr 30;525(2):313-318. doi: 10.1016/j.bbrc.2020.02.086. Epub 2020 Feb 20.

PMID:
32087973
7.

Distribution of BCG-CWS-Loaded Nanoparticles in the Spleen After Intravenous Injection Affects Cytotoxic T Lymphocyte Activity.

Masuda H, Nakamura T, Harashima H.

J Pharm Sci. 2020 Feb 15. pii: S0022-3549(20)30080-0. doi: 10.1016/j.xphs.2020.02.007. [Epub ahead of print]

PMID:
32070704
8.

The Effect of Size and Charge of Lipid Nanoparticles Prepared by Microfluidic Mixing on Their Lymph Node Transitivity and Distribution.

Nakamura T, Kawai M, Sato Y, Maeki M, Tokeshi M, Harashima H.

Mol Pharm. 2020 Mar 2;17(3):944-953. doi: 10.1021/acs.molpharmaceut.9b01182. Epub 2020 Feb 5.

PMID:
31990567
9.

Therapeutic Strategies for Regulating Mitochondrial Oxidative Stress.

Yamada Y, Takano Y, Satrialdi, Abe J, Hibino M, Harashima H.

Biomolecules. 2020 Jan 5;10(1). pii: E83. doi: 10.3390/biom10010083. Review.

10.

The optimization of cancer photodynamic therapy by utilization of a pi-extended porphyrin-type photosensitizer in combination with MITO-Porter.

Satrialdi, Munechika R, Biju V, Takano Y, Harashima H, Yamada Y.

Chem Commun (Camb). 2020 Jan 23;56(7):1145-1148. doi: 10.1039/c9cc08563g.

PMID:
31895356
11.

Targeting Tumor Endothelial Cells with Nanoparticles.

Sakurai Y, Akita H, Harashima H.

Int J Mol Sci. 2019 Nov 20;20(23). pii: E5819. doi: 10.3390/ijms20235819. Review.

12.

Hydrophobic scaffolds of pH-sensitive cationic lipids contribute to miscibility with phospholipids and improve the efficiency of delivering short interfering RNA by small-sized lipid nanoparticles.

Sato Y, Okabe N, Note Y, Hashiba K, Maeki M, Tokeshi M, Harashima H.

Acta Biomater. 2020 Jan 15;102:341-350. doi: 10.1016/j.actbio.2019.11.022. Epub 2019 Nov 13.

13.

A nanocarrier for the mitochondrial delivery of nucleic acids to cardiomyocytes.

Yamada Y, Fujishita N, Harashima H.

Nucleosides Nucleotides Nucleic Acids. 2019 Oct 9:1-15. doi: 10.1080/15257770.2019.1675167. [Epub ahead of print]

PMID:
31595823
14.

The Arabidopsis Cdk1/Cdk2 homolog CDKA;1 controls chromosome axis assembly during plant meiosis.

Yang C, Sofroni K, Wijnker E, Hamamura Y, Carstens L, Harashima H, Stolze SC, Vezon D, Chelysheva L, Orban-Nemeth Z, Pochon G, Nakagami H, Schlögelhofer P, Grelon M, Schnittger A.

EMBO J. 2020 Feb 3;39(3):e101625. doi: 10.15252/embj.2019101625. Epub 2019 Sep 26.

15.

Spleen selective enhancement of transfection activities of plasmid DNA driven by octaarginine and an ionizable lipid and its implications for cancer immunization.

Kimura S, Khalil IA, Elewa YHA, Harashima H.

J Control Release. 2019 Nov 10;313:70-79. doi: 10.1016/j.jconrel.2019.09.009. Epub 2019 Sep 14.

PMID:
31526828
16.

Targeted mitochondrial delivery of antisense RNA-containing nanoparticles by a MITO-Porter for safe and efficient mitochondrial gene silencing.

Kawamura E, Hibino M, Harashima H, Yamada Y.

Mitochondrion. 2019 Nov;49:178-188. doi: 10.1016/j.mito.2019.08.004. Epub 2019 Aug 28.

PMID:
31472283
17.

Recent advances in the targeting of systemically administered non-viral gene delivery systems.

Khalil IA, Sato Y, Harashima H.

Expert Opin Drug Deliv. 2019 Oct;16(10):1037-1050. doi: 10.1080/17425247.2019.1656196. Epub 2019 Aug 21. Review.

PMID:
31432700
18.

A Multifunctional Lipid-Based Nanodevice for the Highly Specific Codelivery of Sorafenib and Midkine siRNA to Hepatic Cancer Cells.

Younis MA, Khalil IA, Abd Elwakil MM, Harashima H.

Mol Pharm. 2019 Sep 3;16(9):4031-4044. doi: 10.1021/acs.molpharmaceut.9b00738. Epub 2019 Aug 23.

PMID:
31403802
19.

Hyaluronan-modified nanoparticles for tumor-targeting.

Sakurai Y, Harashima H.

Expert Opin Drug Deliv. 2019 Sep;16(9):915-936. doi: 10.1080/17425247.2019.1645115. Epub 2019 Aug 6.

PMID:
31387408
20.

The silencing of indoleamine 2,3-dioxygenase 1 (IDO1) in dendritic cells by siRNA-loaded lipid nanoparticles enhances cell-based cancer immunotherapy.

Endo R, Nakamura T, Kawakami K, Sato Y, Harashima H.

Sci Rep. 2019 Aug 5;9(1):11335. doi: 10.1038/s41598-019-47799-w.

21.

A mitochondrial delivery system using liposome-based nanocarriers that target myoblast cells.

Katayama T, Kinugawa S, Takada S, Furihata T, Fukushima A, Yokota T, Anzai T, Hibino M, Harashima H, Yamada Y.

Mitochondrion. 2019 Nov;49:66-72. doi: 10.1016/j.mito.2019.07.005. Epub 2019 Jul 19.

PMID:
31326598
22.

Innovative nanotechnologies for enhancing nucleic acids/gene therapy: Controlling intracellular trafficking to targeted biodistribution.

Nakamura T, Yamada Y, Sato Y, Khalil IA, Harashima H.

Biomaterials. 2019 Oct;218:119329. doi: 10.1016/j.biomaterials.2019.119329. Epub 2019 Jul 4. Review.

PMID:
31306827
23.

Synergistic Enhancement of Cellular Uptake With CD44-Expressing Malignant Pleural Mesothelioma by Combining Cationic Liposome and Hyaluronic Acid-Lipid Conjugate.

Sakurai Y, Kato A, Hida Y, Hamada J, Maishi N, Hida K, Harashima H.

J Pharm Sci. 2019 Oct;108(10):3218-3224. doi: 10.1016/j.xphs.2019.06.012. Epub 2019 Jun 21.

PMID:
31229434
24.

A study of the endocytosis mechanism and transendothelial activity of lung-targeted GALA-modified liposomes.

Santiwarangkool S, Akita H, Khalil IA, Abd Elwakil MM, Sato Y, Kusumoto K, Harashima H.

J Control Release. 2019 Aug 10;307:55-63. doi: 10.1016/j.jconrel.2019.06.009. Epub 2019 Jun 8.

PMID:
31185231
25.

Enhanced autophagy induction via the mitochondrial delivery of methylated β-cyclodextrin-threaded polyrotaxanes using a MITO-Porter.

Yamada Y, Daikuhara S, Tamura A, Nishida K, Yui N, Harashima H.

Chem Commun (Camb). 2019 Jun 25;55(50):7203-7206. doi: 10.1039/c9cc03272j. Epub 2019 Jun 5.

PMID:
31165120
26.

The Cdk1/Cdk2 homolog CDKA;1 controls the recombination landscape in Arabidopsis.

Wijnker E, Harashima H, Müller K, Parra-Nuñez P, de Snoo CB, van de Belt J, Dissmeyer N, Bayer M, Pradillo M, Schnittger A.

Proc Natl Acad Sci U S A. 2019 Jun 18;116(25):12534-12539. doi: 10.1073/pnas.1820753116. Epub 2019 Jun 4.

27.

The Use of a Microfluidic Device to Encapsulate a Poorly Water-Soluble Drug CoQ10 in Lipid Nanoparticles and an Attempt to Regulate Intracellular Trafficking to Reach Mitochondria.

Hibino M, Yamada Y, Fujishita N, Sato Y, Maeki M, Tokeshi M, Harashima H.

J Pharm Sci. 2019 Aug;108(8):2668-2676. doi: 10.1016/j.xphs.2019.04.001. Epub 2019 Apr 5.

PMID:
30959057
28.

Cardiomyopathy in children with mitochondrial disease: Prognosis and genetic background.

Imai-Okazaki A, Kishita Y, Kohda M, Mizuno Y, Fushimi T, Matsunaga A, Yatsuka Y, Hirata T, Harashima H, Takeda A, Nakaya A, Sakata Y, Kogaki S, Ohtake A, Murayama K, Okazaki Y.

Int J Cardiol. 2019 Mar 15;279:115-121. doi: 10.1016/j.ijcard.2019.01.017. Epub 2019 Jan 5.

PMID:
30642647
29.

Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo.

Sato Y, Hashiba K, Sasaki K, Maeki M, Tokeshi M, Harashima H.

J Control Release. 2019 Feb 10;295:140-152. doi: 10.1016/j.jconrel.2019.01.001. Epub 2019 Jan 2.

PMID:
30610950
30.

Mitochondrial ribosomal protein PTCD3 mutations cause oxidative phosphorylation defects with Leigh syndrome.

Borna NN, Kishita Y, Kohda M, Lim SC, Shimura M, Wu Y, Mogushi K, Yatsuka Y, Harashima H, Hisatomi Y, Fushimi T, Ichimoto K, Murayama K, Ohtake A, Okazaki Y.

Neurogenetics. 2019 Mar;20(1):9-25. doi: 10.1007/s10048-018-0561-9. Epub 2019 Jan 3.

PMID:
30607703
31.

Mixing lipids to manipulate the ionization status of lipid nanoparticles for specific tissue targeting.

Shobaki N, Sato Y, Harashima H.

Int J Nanomedicine. 2018 Dec 10;13:8395-8410. doi: 10.2147/IJN.S188016. eCollection 2018.

32.

The delivery of mRNA to colon inflammatory lesions by lipid-nano-particles containing environmentally-sensitive lipid-like materials with oleic acid scaffolds.

Tanaka H, Watanabe A, Konishi M, Nakai Y, Yoshioka H, Ohkawara T, Takeda H, Harashima H, Akita H.

Heliyon. 2018 Dec 3;4(12):e00959. doi: 10.1016/j.heliyon.2018.e00959. eCollection 2018 Dec.

33.

Effective Therapy Using a Liposomal siRNA that Targets the Tumor Vasculature in a Model Murine Breast Cancer with Lung Metastasis.

Sakurai Y, Hada T, Kato A, Hagino Y, Mizumura W, Harashima H.

Mol Ther Oncolytics. 2018 Oct 30;11:102-108. doi: 10.1016/j.omto.2018.10.004. eCollection 2018 Dec 21.

34.

Genome-wide identification of RETINOBLASTOMA RELATED 1 binding sites in Arabidopsis reveals novel DNA damage regulators.

Bouyer D, Heese M, Chen P, Harashima H, Roudier F, Grüttner C, Schnittger A.

PLoS Genet. 2018 Nov 30;14(11):e1007797. doi: 10.1371/journal.pgen.1007797. eCollection 2018 Nov.

35.

Critical parameters dictating efficiency of membrane-mediated drug transfer using nanoparticles.

Abbasi S, Kajimoto K, Harashima H.

Int J Pharm. 2018 Dec 20;553(1-2):398-407. doi: 10.1016/j.ijpharm.2018.10.042. Epub 2018 Oct 26.

36.

Application of BCG-CWS as a Systemic Adjuvant by Using Nanoparticulation Technology.

Masuda H, Nakamura T, Noma Y, Harashima H.

Mol Pharm. 2018 Dec 3;15(12):5762-5771. doi: 10.1021/acs.molpharmaceut.8b00919. Epub 2018 Nov 8.

PMID:
30380885
37.

Optimization of siRNA delivery to target sites: issues and future directions.

Khalil IA, Yamada Y, Harashima H.

Expert Opin Drug Deliv. 2018 Nov;15(11):1053-1065. doi: 10.1080/17425247.2018.1520836. Epub 2018 Sep 25. Review.

PMID:
30198792
38.

DNA-loaded nano-adjuvant formed with a vitamin E-scaffold intracellular environmentally-responsive lipid-like material for cancer immunotherapy.

Kawai M, Nakamura T, Miura N, Maeta M, Tanaka H, Ueda K, Higashi K, Moribe K, Tange K, Nakai Y, Yoshioka H, Harashima H, Akita H.

Nanomedicine. 2018 Nov;14(8):2587-2597. doi: 10.1016/j.nano.2018.08.006. Epub 2018 Aug 29.

PMID:
30170077
39.

The use of cardiac progenitor cells for transplantation in congenital heart disease and an innovative strategy for activating mitochondrial function in such cells.

Abe J, Yamada Y, Harashima H.

J Thorac Dis. 2018 Jul;10(Suppl 18):S2119-S2121. doi: 10.21037/jtd.2018.06.76. No abstract available.

40.

Neutralization of negative charges of siRNA results in improved safety and efficient gene silencing activity of lipid nanoparticles loaded with high levels of siRNA.

Sato Y, Matsui H, Sato R, Harashima H.

J Control Release. 2018 Aug 28;284:179-187. doi: 10.1016/j.jconrel.2018.06.017. Epub 2018 Jun 21.

41.

Development of the iLiNP Device: Fine Tuning the Lipid Nanoparticle Size within 10 nm for Drug Delivery.

Kimura N, Maeki M, Sato Y, Note Y, Ishida A, Tani H, Harashima H, Tokeshi M.

ACS Omega. 2018 May 9;3(5):5044-5051. doi: 10.1021/acsomega.8b00341. eCollection 2018 May 31.

42.

Haptic-based perception-empathy biofeedback system for balance rehabilitation in patients with chronic stroke: Concepts and initial feasibility study.

Yasuda K, Saichi K, Kaibuki N, Harashima H, Iwata H.

Gait Posture. 2018 May;62:484-489. doi: 10.1016/j.gaitpost.2018.04.013. Epub 2018 Apr 14.

PMID:
29677663
43.

A hepatic pDNA delivery system based on an intracellular environment sensitive vitamin E-scaffold lipid-like material with the aid of an anti-inflammatory drug.

Togashi R, Tanaka H, Nakamura S, Yokota H, Tange K, Nakai Y, Yoshioka H, Harashima H, Akita H.

J Control Release. 2018 Jun 10;279:262-270. doi: 10.1016/j.jconrel.2018.04.022. Epub 2018 Apr 17.

PMID:
29673647
44.

Reducing the Cytotoxicity of Lipid Nanoparticles Associated with a Fusogenic Cationic Lipid in a Natural Killer Cell Line by Introducing a Polycation-Based siRNA Core.

Nakamura T, Yamada K, Fujiwara Y, Sato Y, Harashima H.

Mol Pharm. 2018 Jun 4;15(6):2142-2150. doi: 10.1021/acs.molpharmaceut.7b01166. Epub 2018 Apr 30.

PMID:
29668291
45.

In Vivo Introduction of mRNA Encapsulated in Lipid Nanoparticles to Brain Neuronal Cells and Astrocytes via Intracerebroventricular Administration.

Tanaka H, Nakatani T, Furihata T, Tange K, Nakai Y, Yoshioka H, Harashima H, Akita H.

Mol Pharm. 2018 May 7;15(5):2060-2067. doi: 10.1021/acs.molpharmaceut.7b01084. Epub 2018 Apr 11.

PMID:
29638135
46.

Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems.

Maeki M, Kimura N, Sato Y, Harashima H, Tokeshi M.

Adv Drug Deliv Rev. 2018 Mar 15;128:84-100. doi: 10.1016/j.addr.2018.03.008. Epub 2018 Mar 19. Review.

PMID:
29567396
47.

Synergism between a cell penetrating peptide and a pH-sensitive cationic lipid in efficient gene delivery based on double-coated nanoparticles.

Khalil IA, Kimura S, Sato Y, Harashima H.

J Control Release. 2018 Apr 10;275:107-116. doi: 10.1016/j.jconrel.2018.02.016. Epub 2018 Feb 13.

48.

Mitochondrial transgene expression via an artificial mitochondrial DNA vector in cells from a patient with a mitochondrial disease.

Ishikawa T, Somiya K, Munechika R, Harashima H, Yamada Y.

J Control Release. 2018 Mar 28;274:109-117. doi: 10.1016/j.jconrel.2018.02.005. Epub 2018 Feb 3.

49.

An efficient PEGylated gene delivery system with improved targeting: Synergism between octaarginine and a fusogenic peptide.

Khalil IA, Harashima H.

Int J Pharm. 2018 Mar 1;538(1-2):179-187. doi: 10.1016/j.ijpharm.2018.01.007. Epub 2018 Jan 16.

50.

Barth Syndrome: Different Approaches to Diagnosis.

Imai-Okazaki A, Kishita Y, Kohda M, Yatsuka Y, Hirata T, Mizuno Y, Harashima H, Hirono K, Ichida F, Noguchi A, Yoshida M, Tokorodani C, Nishiuchi R, Takeda A, Nakaya A, Sakata Y, Murayama K, Ohtake A, Okazaki Y.

J Pediatr. 2018 Feb;193:256-260. doi: 10.1016/j.jpeds.2017.09.075. Epub 2017 Dec 15.

PMID:
29249525

Supplemental Content

Loading ...
Support Center